Adding a mineral supplement to standard lung cancer treatment

Plain-English translation of NCT07149649 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether magnesium aspartate hydrochloride — a mineral supplement taken by mouth and through an IV — can enhance how well your immune system fights lung cancer when combined with standard chemotherapy and immunotherapy. Chemotherapy can lower magnesium levels in your body, which may weaken your immune response. Researchers believe correcting this deficiency might help your body's cancer-fighting cells work better.

Standard chemotherapy for advanced lung cancer often depletes magnesium in the body, and early research suggests this might reduce how effectively immunotherapy works. This trial exists to find out whether replacing that lost mineral can strengthen your immune system's ability to fight the cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced (stage III or IV) non-small cell lung cancer that cannot be removed by surgery
you are scheduled to start first-line chemotherapy combined with immunotherapy (PD-1 or PD-L1 inhibitors)
you have not received chemotherapy or immunotherapy for your metastatic lung cancer before
you are 18 years or older and in good enough general health to tolerate treatment
you have adequate kidney and liver function based on blood tests
your cancer does not have specific genetic mutations (like EGFR or ALK) that would qualify you for different treatment

You likely don't qualify if…

you are already taking magnesium supplements or need them for another medical reason
you have severe magnesium deficiency that needs immediate correction
you are eligible for immunotherapy alone (single-drug treatment) instead of combination therapy
you have severely impaired kidney function or cannot tolerate intravenous medications
you have active, untreated brain metastases or require ongoing steroid treatment for brain cancer

What participation looks like

You will receive standard chemotherapy and immunotherapy every 3 weeks (the backbone of treatment for all participants). In addition, you will either receive magnesium supplements — an oral tablet three times daily during each treatment cycle plus an IV infusion on the first day of each cycle — or a matching placebo. Your magnesium levels will be monitored regularly through blood and urine samples. The study team will watch carefully for any side effects and how well the treatment works, with visits scheduled around your regular chemotherapy appointments.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(11 sites)

Switzerland

Tumorzentrum Aarau - Hirslanden TZA, Aarau

Kantonsspital Aarau, Aarau

Kantonsspital Baden, Baden

St. Claraspital, Basel

Universitätsspital Basel, Basel